A Study of Q-1802 in Patients With Advanced Solid Tumors

A Phase I Clinical Trial to Evaluate the Safety, Tolerability and Efficacy of Q-1802 in Patients With Advanced Solid Tumors

Q-1802 is a bispecific antibody targeting both the tumor-specific antigen Claudin 18.2 and the immune checkpoint PD-L1. This is a multi-center, single-arm, open-label design to evaluate the safety and tolerance of Q-1802 in patients with advanced solid tumors, together with an assessment of pharmacokinetic characteristics and efficacy. The study consisted of two compartments: the dose-exploration stage and the dose-extension stage.

Study Overview

• Status: Recruiting
• Conditions: Advanced Solid Tumors
• Intervention / Treatment: Drug: Q-1802

• Study Type: Interventional
• Enrollment (Estimated): 66
• Phase: Phase 1

Contacts and Locations

• Study Contact: Name: Xu Liang; Phone Number: 021-50920280; Email: liangxu@qurebio.com

Study Locations

• China
  • Beijing, China
    • Recruiting
    • Beijing cancer hospical
    • Contact: Lin Shen
  • Chengdu, China
    • Recruiting
    • West China Second University Hospical, Sichuan University
    • Contact: Qin Yu
  • Shanghai, China
    • Recruiting
    • Fudan University Shanghai Cancer Center
    • Contact: Jian Zhang
  • Zibo, China
    • Recruiting
    • PKUcare Luzhong Hospital
    • Contact: Jie Hou

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 75 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Male or female, age ≥18 years and ≤75 years.
• Patients with at least one measurable lesion per RECIST (v1.1) (applicable to the dose-extension stage).
• Eastern Cooperative Oncology Group (ECOG) performance status score 0 or 1 at screening and no deterioration occurs within two weeks before enrollment.
• Life expectancy period ≥ 12 weeks.
• Patients who have sufficient baseline organ function and whose laboratory data meet the following criteria (receiving no treatment of blood transfusions, albumin, recombinant human thrombopoietin, or colony-stimulating factor within 14 days before the first dose of this study).
• Patients with advanced gastric mucinous adenocarcinoma, advanced ovarian mucinous carcinoma or other dominant tumors participating in the dose-extension stage must provide eligible tumor tissue samples for biomarker detection; if subjects agree, tumor tissue samples should also be provided during the dose-exploration stage.

Exclusion Criteria:

• Patients who have received any prior PD-1/PD-L1 antibody therapy (applicable to the dose-exploration stage).
• Patients with uncontrolled blood pressure (systolic blood pressure ≥ 150 mm Hg and/or diastolic blood pressure ≥ 100 mm Hg) or previous hypertensive crisis or hypertensive encephalopathy.
• Patients with active peptic ulcer, gastric outlet obstruction or persistent recurrent vomiting.
• Patients with a history of monoclonal antibody allergic reaction.
• Patients who are considered ineligible by the investigator due to any other severe, acute or chronic disease or other causes that the investigator considers could affect the patient's participation or assessment in the study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Q-1802; Q-1802 dose exploration and Q-1802 dose extension	Drug: Q-1802; Q-1802 will be administered intravenously.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of participants with dose limiting toxicities	Incidence of dose limiting toxicities(DLTs). A DLT is defined as an adverse event or abnormal laboratory value assessed as unrelated to disease, disease progression, inter-current illness, or concomitant medications that occurs within the first treatment cycle with Q-1802.	28 days

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Plasma concentration (Cmax)	Highest observed plasma concentration of Q-1802	70 days
Time to achieve Cmax (Tmax)	Time of highest observed plasma concentration of Q-1802	70 days
Area under the plasma concentration-time curve (AUC)	Area under the plasma concentration time curve of Q-1802	70 days
PD-L1 receptor occupancy rate (RO)	PD-L1 receptor occupancy rate (RO) on the surface of T lymphocytes in peripheral blood at different time points of Q-1802	70 days
Number of participants with treatment-related adverse events(TRAE)	TRAE is defined as the AEs that the casual relationship of the AE is ralated to Q-1802.	70 days
Objective response rate (ORR)	ORR is defined as proportion of participants with complete response, partial response (CR+PR).	70 days
Progression-free survival (PFS)	PFS is defined as the interval of time between the date of first treatment to the earliest date of disease progression or death which occurs first.	70 days
Duration of response ( DCR )	DCR is defined as proportion of participants with complete response, partial response, stable disease (CR+PR+SD).	70 days
Duration of response ( DOR )	DOR is defined as the time from the participant's initial objective response (CR or PR) to study drug therapy, to disease progression or death due to any cause, whichever occurs first	70 days

Collaborators and Investigators

• Sponsor: QureBio Ltd.

Study record dates

Study Major Dates

• Study Start (Actual): May 21, 2021
• Primary Completion (Estimated): April 1, 2024
• Study Completion (Estimated): July 1, 2024

Study Registration Dates

• First Submitted: April 19, 2021
• First Submitted That Met QC Criteria: April 19, 2021
• First Posted (Actual): April 23, 2021

Study Record Updates

• Last Update Posted (Actual): July 27, 2023
• Last Update Submitted That Met QC Criteria: July 24, 2023
• Last Verified: July 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms
• Other Study ID Numbers: Qure-1802-101

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No